Financial Gravity Asset Management, Inc. Reata Pharmaceuticals Inc Transaction History

Financial Gravity Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$79.22 - $105.37 $871 - $1,159	11 Added 12.09%	102 $50,000
Q1 2023 May 12, 2023	BUY	$30.85 - $93.17 $1,635 - $4,938	53 Added 139.47%	91 $14,000
Q4 2022 Feb 15, 2023	SELL	$22.15 - $42.11 $265 - $505	-12 Reduced 24.0%	38 $19,000
Q3 2022 Nov 03, 2022	BUY	$19.41 - $36.49 $970 - $1,824	50 New	50 $4,000
Q4 2021 Feb 11, 2022	SELL	$25.61 - $110.96 $0 - $0	0 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$100.0 - $143.02 $0 - $0	0 New	0 $101,000
Q2 2021 Aug 11, 2021	BUY	$78.27 - $151.29 $0 - $0	0 New	0 $142,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.